Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Bluejay Diagnostics (BJDX) Long-Term Debt Repayments (2021 - 2024)

Bluejay Diagnostics recorded quarterly Long-Term Debt Repayments of $147440.0 in Q3 2024, down 46.04% quarter-over-quarter from $273225.0 in Q3 2021.

Bluejay Diagnostics' Long-Term Debt Repayments history runs 2 years deep, the most recent figure standing at $147440.0 for Q3 2024.

  • In Q3 2024, Long-Term Debt Repayments changed N/A year-over-year to $147440.0; the TTM figure through Dec 2024 stood at $420665.0 (changed N/A YoY), while the FY2024 annual figure was $2.0 million, changed N/A from the prior year.
  • Long-Term Debt Repayments came in at $147440.0 for Q3 2024 at Bluejay Diagnostics, down from $273225.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $273225.0 in Q3 2021 to a low of $21617.0 in Q2 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.42 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.00 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Bluejay Diagnostics 572,394.44 -3.11 Mn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2024 147,440.00
Sep 30, 2024 147,440.00
Sep 30, 2021 273,225.00
Sep 30, 2021 273,225.00
Jun 30, 2021 21,617.00
Jun 30, 2021 21,617.00
Mar 31, 2021 268,000.00
Mar 31, 2021 268,000.00